TLE2 is a transcriptional corepressor that functions as a negative regulator of gene expression through multiple mechanistic pathways. As a member of the TLE family, TLE2 inhibits transcriptional activation mediated by CTNNB1 and TCF family members in Wnt signaling 1. TLE2 operates by binding to various transcription factors and recruiting them to DNA regulatory elements, where it suppresses their activation capacity 2. In developmental contexts, TLE2 cooperates with transcription factors like FoxG1 through conserved binding motifs to specify neural tissue identity 3. Clinically, TLE2 exhibits context-dependent roles in disease. In pancreatic ductal adenocarcinoma (PDAC), elevated TLE2 expression correlates with improved prognosis and functions as a tumor suppressor, enhancing gemcitabine sensitivity and suppressing cell proliferation 4. Conversely, in cancer stem cell biology, TLE2 suppression increases side population cells and enhances tumorigenicity through hedgehog pathway activation 5. In age-related macular degeneration, TLE2 emerges as a mechanistic regulator of Wnt signaling dysregulation 1. Recent evidence reveals that DDX3X-mediated destabilization of TLE2 mRNA promotes pancreatic cancer metastasis by disrupting KLF4 interaction and increasing MYL9 expression 6. These findings establish TLE2 as a contextual tumor suppressor with therapeutic potential in select malignancies and retinal disease.